A double-blind phase 3 trial in Japan found that a combination of trifluridine and tipiracil significantly prolonged survival in patients with metastatic stomach cancer. These drugs improved overall survival compared to placebo regardless of gastrectomy. Results showed a 31 percent risk reduction of death which translates into an average increased survival time of 2.1 months compared to placebo.

View Full Article
Read More